Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy

被引：44

作者：

Burnett, AF

Bahador, A

Amezcua, C

机构：

[1] Univ So Calif, Div Gynecol Oncol, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA

[2] City Hope Natl Med Ctr, Div Gynecol Oncol, Duarte, CA 91010 USA

[3] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA

来源：

GYNECOLOGIC ONCOLOGY | 2004年 / 94卷 / 03期

关键词：

anastrazole; medroxyprogesterone acetate; hysterectomy;

D O I：

10.1016/j.ygyno.2004.06.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background. Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility. Combining progesterone with an agent that eliminates the adipose production of estrogen will theoretically be more effective than progesterone alone. Cases. Two cases of reproductive-aged women with grade 1 endometrial cancer who were treated with medroxyprogesterone acetate and anastrozole daily for 3 and 6 months subsequently reverted to normal endometrium. Conclusion. Progesterone combined with the elimination of adipose production of estrogen may be an effective therapy in well-differentiated endometrial cancer in the obese premenopausal woman. (C) 2004 Elsevier Inc. All rights reserved.

引用

页码：832 / 834

页数：3

共 12 条

[1]

'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview [J].